Catalent celebrates opening of second Shanghai facility

14 Apr 2019

Catalent’s two Shanghai locations will provide sponsors with an optimized supply solution for studies being undertaken in China, the Asia-Pacific region and globally.

Catalent Pharma Solutions has completed its new, 30,000-sq ft clinical supply facility in Shanghai, China. The event was marked with an official opening ceremony at the site on 10 April.

Catalent celebrates opening of second Shanghai facility

The facility, located outside of the free trade zone (FTZ) in Tangzhen, is near to both Catalent’s existing Waigaoqiao FTZ site and China’s Zhangjiang Pharma Valley area. Together, Catalent’s two Shanghai locations will provide sponsors with an optimized supply solution for studies being undertaken in China, the Asia-Pacific region and globally. It is expected to employ up to 100 people and offers comprehensive clinical supply services including FastChain demand-led supply, secondary packaging, clinical storage and local distribution, as well as clinical returns and destruction services.

At the ribbon-cutting ceremony to officially open the site, Catalent executives welcomed local government officials and local and international pharma customers. Guests were accompanied on a site tour, and the opening ceremony also featured a traditional Chinese lion dance and a symbolic light display to reflect the bright future of the site’s foundations.

“We are delighted to have already engaged customers for services in Tangzhen,” commented Roel de Nobel, Vice President, Global Operations, Catalent Clinical Supply Services. He added, “Having facilities both inside and outside the FTZ in China affords customers flexibility, convenience and streamlined logistics in support of the growing number of trials being conducted in the region.”

The Tangzhen opening follows recent investments in Singapore and Japan, strengthening Catalent’s capabilities to support clinical trials in Asia and beyond.

Read More

Related news

Catalent to acquire gene therapy leader Paragon Bioservices

Catalent to acquire gene therapy leader Paragon Bioservices

16 Apr 2019

Will provide new expertise and capabilities in one of the fastest-growing areas of healthcare.

Read more 
Colorcon expands functional film coatings through the CR Alliance with DuPont

Colorcon expands functional film coatings through the CR Alliance with DuPont

15 Apr 2019

The Aquacoat product line provides modified release drug profiles with the added benefit of global regulatory acceptance.

Read more 
Hovione Technology acquires global rights to new pulmonary inhaler device

Hovione Technology acquires global rights to new pulmonary inhaler device

15 Apr 2019

The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.

Read more 
Exploristics surges ahead with £1m investment

Exploristics surges ahead with £1m investment

15 Apr 2019

The loan will be used to develop KERUS Cloud - currently the only software that can simulate trials with multiple correlated outcomes - by integrating it into an intelligent software ecosystem.

Read more 
Global collaboration to innovate more natural and additive-free nutraceuticals

Global collaboration to innovate more natural and additive-free nutraceuticals

12 Apr 2019

Initiative will enable Sirio Pharma to keep abreast of regional trends, new ingredients, dosage forms and claims to provide customers unique product ideas for line extensions.

Read more 
Isotype-specific secondary antibodies for improved signal detection

Isotype-specific secondary antibodies for improved signal detection

10 Apr 2019

Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.

Read more 
Sterling Pharma to acquire CiVentiChem in the US

Sterling Pharma to acquire CiVentiChem in the US

9 Apr 2019

The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.

Read more 
New China-based biotechs fueling growth in manufacturing across China

New China-based biotechs fueling growth in manufacturing across China

9 Apr 2019

New guidelines will see poorer quality manufacturers drop out of the market.

Read more 
TTP spin-out to commercialise next-generation cell-sorting technology

TTP spin-out to commercialise next-generation cell-sorting technology

7 Apr 2019

Highway 1 addresses a major unmet need for improved cell-sorting technology, with applications including development of cell therapies, liquid biopsy diagnostics, and high-throughput drug discovery.

Read more 
Catalent expands OptiMelt hot melt extrusion capabilities

Catalent expands OptiMelt hot melt extrusion capabilities

4 Apr 2019

The investment includes the addition of equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.

Read more